April 2015

New Product - Visanne

Visanne (dienogest) is a nortestosterone derivative with antiandrogenic activity of approximately one third of that of cyproterone acetate. Dienogest acts on endometriosis by reducing the endogenous production of oestradiol and thereby suppressing the trophic effects of oestradiol on both the eutopic and ectopic endometrium. When given continuously, dienogest leads to a hypoestrogenic, hypergestagenic endocrine environment causing initial decidualisation of endometrial tissue followed by atrophy of endometriotic lesions. Additional properties, like immunologic and antiangiogenic effects, seem to contribute to the inhibitory action of dienogest on cell proliferation. Visanne is indicated for the treatment of endometriosis. Visanne should not be used in the presence of any of the following conditions, which are partially derived from information on other progestogen only preparations. Should any of the conditions appear during the use of Visanne, treatment must be discontinued immediately. Known or suspected pregnancy; lactation; active venous thromboembolic disorder; arterial and cardiovascular disease, present or in history (e.g. myocardial infarction, cerebrovascular accident, ischaemic heart disease); diabetes mellitus with vascular involvement; present or history of severe hepatic disease as long as liver function values have not returned to normal; present or history of liver tumours (benign or malignant); known or suspected sex hormone dependent malignancies; and undiagnosed vaginal bleeding. Visanne 2 mg tablets are available in cartons of 28’s (blister pack of 2 x 14).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629